RZ001

Drug

Related News

Rznomics to present interim U.S. trial results for liver cancer candidate RZ-001 at AACR

Apr 19, 2026

Rznomics said it will present interim AACR results for liver cancer candidate RZ-001 from a U.S. trial in patients with hepatocellular carcinoma. Tumor-shrinking responses were observed, and about 23% experienced complete disappearance of cancer cells.

Cancer Pipeline Reports Show 45+ CSCC, 70+ Liver Cancer, and Multiple HCC Therapies in Development

Mar 20, 2026

DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.